Chen, Tianxiang
Cao, Zhengqi
Sun, Yingjia
Huang, Jia
Shen, Shengping
Jin, Yueping
Jiang, Long
Wen, Fengcai
Zhao, Xiaochen
Zhang, Ding
Chen, Yanan
Huang, Mengli
Chen, Hao
Lu, Shun
Li, Ziming
Funding for this research was provided by:
National Multi-disciplinary Treatment Project for Major Diseases (2020NMDTP)
Lian Yun Gang Shi Hui Lan Public Foundation (HL-HS2020-65)
The Innovative Research Team of High-level Local Universities in Shanghai (SHSMU-ZLCX20212302)
Shanghai youth talent support program, Shanghai Chest Hospital Project of Collaborative Innovative Grant (YJT20190209)
Guangdong Association of Clinical Trials (GACT)/Chinese Thoracic Oncology Group (CTONG) and Guangdong Provincial Key Lab of Translational Medicine in Lung Cancer (2017B030314120)
Shanghai Chest Hospital Project of talent support (2018YNZYJ02)
Project of Shanghai Natural Science Foundation (20ZR1452000)
Program of Shanghai Academic Research Leader (22XD142280)
National Natural Science Foundation of China (82072564, 82272679)
Shanghai Municipal Health Commission (2022XD029)
Article History
Received: 22 November 2022
Accepted: 9 July 2023
First Online: 16 August 2023
Disclosures
: Fengcai Wen, Xiaochen Zhao, Ding Zhang, Mengli Huang, Yanan Chen, and Hao Chen were employed by 3D Medicines-Shanghai Inc. Tianxiang Chen, Zhengqi Cao, Yingjia Sun, Jia Huang, Shengping Shen, Yueping Jin, Long Jiang, Shun Lu, and Ziming Li declare that this research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.